InvestorsHub Logo
Followers 43
Posts 1706
Boards Moderated 0
Alias Born 02/28/2019

Re: None

Sunday, 03/31/2019 3:54:25 PM

Sunday, March 31, 2019 3:54:25 PM

Post# of 316
ADMA Biologics Inc
ADMA 13.98%
awaits FDA nod for its BLA for RI-002, which is being evaluated as a treatment option for Primary Immune Deficiency Disease, or PIDD. The PDUFA date is scheduled for April 2.

https://www.benzinga.com/general/biotech/19/03/13443439/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trials-ear


Target Price $10.00 with a Buy rating

https://www.finviz.com/quote.ashx?t=adma
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADMA News